amitriptyline (inhibitor) — SERT + NET + H1 + M1 + α1 + Na channel. sedating TCA; chronic pain + migraine prophylaxis + insomnia at low doses; depression at high; overdose-lethal narrow TI
nortriptyline (inhibitor) — NET > SERT + H1/M1/α1. amitriptyline's active metabolite; cleaner profile than parent; lower anticholinergic load; therapeutic drug monitoring
imipramine (inhibitor) — SERT + NET + H1 + M1. first TCA (1957); depression + childhood enuresis (peripheral anticholinergic on bladder)
clomipramine (inhibitor) — SERT > NET (most serotonergic TCA). OCD; SSRI-like serotonergic activity; canine OCD label (Clomicalm)
doxepin (inhibitor) — SERT + H1 (potent) + NET + α1. antidepressant + chronic urticaria + insomnia at low dose (3-6 mg Silenor — H1 antagonism); CYP2D6 substrate
doxepin low dose (inhibitor) — H1 (selective at low dose). Silenor 3-6 mg insomnia; pure H1 antagonist at this dose; no anticholinergic side effects
mirtazapine (inhibitor) — α2 + 5-HT2A/2C + 5-HT3 + H1. tetracyclic; sedation + appetite stimulation; minimal sexual side effects vs SSRIs; weight gain
bupropion (inhibitor) — NET + DAT (NDRI). NDRI; depression + smoking cessation (Zyban) + ADHD off-label; minimal sexual side effects; seizure risk at high doses (eating disorders contraindicated)
vilazodone (inhibitor) — SERT + 5-HT1A partial agonist (SPARI). serotonin partial-agonist reuptake inhibitor; modest GI side effects; lower sexual side effects vs SSRIs